Merck Sharp & Dohme Corp: V591

Vaccine Type: Replicating Viral Vector

Vaccine Trial & Approval Tracker

This vaccine has reached Phase 2 trials.

About Trial Phases

Phase 1: 1 Trial

  • NCT04498247
    Austria, Belgium, United States of America

Phase 2: 1 Trial

  • NCT04498247
    Austria, Belgium, United States of America

Phase 3: 0 Trials

There are no trials for this phase.

Approvals: 0 Approvals

This vaccine is not yet approved.

Registered Trials